Related references
Note: Only part of the references are listed.Predictors of severity and functional outcome in natalizumab-associated progressive multifocal leukoencephalopathy
Robert Hoepner et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Predictors of severity and functional outcome in natalizumab-associated progressive multifocal leukoencephalopathy
Robert Hoepner et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study
Tomas Kalincik et al.
LANCET NEUROLOGY (2017)
Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies
Pei-Ran Ho et al.
LANCET NEUROLOGY (2017)
Natalizumab-associated PML Challenges with incidence, resulting risk, and risk stratification
Nicholas Schwab et al.
NEUROLOGY (2017)
LEVODOPA-INDUCED DYSKINESIA IN PARKINSON'S: A LONGITUDINAL PET STUDY
Andreas-Antonios Roussakis et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2016)
Re-evaluating the incidence of natalizumab-associated progressive multifocal leukoencephalopathy
Julian Borchardt et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2016)
Anti-JC Virus Antibody Levels in Serum or Plasma Further Define Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
Tatiana Plavina et al.
ANNALS OF NEUROLOGY (2014)
Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
Gary Bloomgren et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Share Paper
